Currently, there is an ongoing clinical trial investigating AAV8 containing a transgene for the fragment antigen-binding region of anti-vascular endothelial growth factor (anti-VEGF fab), as a vector for gene therapy of diabetic retinopathy, delivered in the suprachoroidal space [339]. This evidence concerns the gene VEGFA and diabetic retinopathy.